Frazier Life Sciences Management, L.P.: NEWAMSTERDAM PHARMA COMPANY (NAMS): Quarterly 13F Position History
As of Q1 2026, Frazier Life Sciences Management, L.P. reported 16,943,774 shares of NEWAMSTERDAM PHARMA COMPANY (NAMS), worth $542.4M and representing 14.0% of its 13F equity book. The position first appeared in Q4 2022 and has been disclosed across 14 13F-HR filings in Pactolio's tracked window.
- 16,943,774Shares Held (Latest Filing)
- $542.4MReported Market Value (Latest Filing)
- 14.0%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$52.0MQuarter-over-Quarter Value Change
- 16,943,774Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 14 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 16,943,774 | 0 | — | $542.4M | 14.0% | $32.0 |
| Q4 2025 | 16,943,774 | +241,818 | +1.4% | $594.4M | 16.0% | $35.1 |
| Q3 2025 | 16,701,956 | +94,882 | +0.6% | $475.0M | 14.2% | $28.4 |
| Q2 2025 | 16,607,074 | +490,656 | +3.0% | $300.8M | 12.0% | $18.1 |
| Q1 2025 | 16,116,418 | +200,000 | +1.3% | $329.9M | 15.1% | $20.5 |
| Q4 2024 | 15,916,418 | +3,061,224 | +23.8% | $409.1M | 17.0% | $25.7 |
| Q3 2024 | 12,855,194 | +628,251 | +5.1% | $213.4M | 8.6% | $16.6 |
| Q2 2024 | 12,226,943 | 0 | — | $234.9M | 11.0% | $19.2 |
| Q1 2024 | 12,226,943 | +95,238 | +0.8% | $289.2M | 12.2% | $23.6 |
| Q4 2023 | 12,131,705 | 0 | — | $135.5M | 7.2% | $11.2 |
| Q3 2023 | 12,131,705 | +1,259,902 | +11.6% | $112.2M | 7.5% | $9.3 |
| Q2 2023 | 10,871,803 | +1,530,252 | +16.4% | $129.3M | 7.7% | $11.9 |
| Q1 2023 | 9,341,551 | 0 | — | $125.6M | 9.1% | $13.4 |
| Q4 2022 | 9,341,551 | — | — | $101.8M | 6.3% | $10.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Frazier Life Sciences Management, L.P. first disclose a NAMS position in 13F-HR filings?
Frazier Life Sciences Management, L.P. first reported NEWAMSTERDAM PHARMA COMPANY (NAMS) on its 13F-HR filing for the period ending 2022-12-31 (Q4 2022). The position has appeared on 14 reported quarters within Pactolio's tracked window.
What was Frazier Life Sciences Management, L.P.'s most recent quarter-over-quarter share-count change in NAMS?
Frazier Life Sciences Management, L.P. held the same 16,943,774 shares of NAMS between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Frazier Life Sciences Management, L.P.'s cost basis in NAMS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.